CHMP Chairman 
European Medicines Agency 
7 Westferry Circus 
Canary Wharf 
London 
E14 4HB 
United Kingdom 
Date: 12 September 2017 
Subject: Withdrawal of Tigecycline Accord, tigecycline, 50mg/vial, Powder for solution for infusion - 
EMEA/H/C/004419  
Dear CHMP Chairman, 
For the withdrawal of initial marketing authorisation application 
I would like to inform you that, at this point of time, Accord Healthcare Limited, UK has taken the decision 
to  withdraw  the  application  for  Marketing  Authorisation  of  Tigecycline  Accord,  tigecycline,  50mg/vial, 
Powder for solution for infusion which was intended to be used for  
In adults and in children from the age of eight years for the treatment of the following infections: 
• Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections
• Complicated  intra-abdominal  infections  (cIAI)Tigecycline  Accord  should  be  used  only  in  situations
where other alternative antibiotics are not suitable. 
This withdrawal is based on the following reasons: 
Company’s marketing strategy
•
• Other: Drug substance manufacturing sites have been inspected by EU inspectorates and as a
result  of  this  inspection,  Statements  of  GMP  Non-Compliance  have  been  issued  published  on
EudraGMDP.
As  confirmed  with  agency  we  are  already  in  planning  to  develop  the  product  using  alternative  drug 
substance source. 
We  reserve  the  right  to  make  further  submissions  at  a  future  date  in  this  or  other  therapeutic 
indication(s). 
I agree for this letter to be published on the European Medicines Agency website. 
Yours sincerely, 
VP – Regulatory Affairs 
Accord Healthcare Limited, UK 
